Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

101. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared

2019 Health Technology Wales

102. Remote monitoring or self-management for surveillance or follow up of prostate cancer

Remote monitoring or self-management for surveillance or follow up of prostate cancer Remote monitoring of prostate cancer - Health Technology Wales > Remote monitoring of prostate cancer Remote monitoring of prostate cancer Topic Status Incomplete Remote monitoring or self-management for surveillance or follow up of prostate cancer. Summary Health Technology Wales researchers searched for evidence on different methods of prostate remote monitoring/self-management. Although a range of evidence

2019 Health Technology Wales

103. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. Full Text available with Trip Pro

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. Patients with castration-resistant prostate cancer (CRPC) had extended responses to the androgen receptor antagonist ODM-201, in phase 1/2 studies.To evaluate the safety and antitumour activity of prolonged ODM-201 treatment in patients with CRPC.The ARADES trial was a multicentre phase 1 (dose escalation) and phase 2 (dose (...) antitumour activity in men with advanced prostate cancer, indicating that ODM-201 may represent a new active treatment for men with CRPC. This extension trial is registered at ClinicalTrials.gov (www.clinicaltrials.gov) under identification number NCT01429064.Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2019 European urology focus Controlled trial quality: uncertain

104. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings (Abstract)

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings Asians have a lower incidence of prostate cancer (PC). We compared the performance of the Prostate Health Index (PHI) for 2488 men in different ethnic groups (1688 Asian and 800 European men from 9 sites) with PSA 2-20ng/ml and PHI test and transrectal ultrasound-guided biopsy results (...) ) and for PSA 10-20ng/ml (n=439). PHI is effective in cancer risk stratification for both European and Asian men. However, population-specific PHI reference ranges should be used. PATIENT SUMMARY: The Prostate Health Index (PHI) blood test helps to identify individuals at higher risk of prostate cancer among Asian and European men, and could significantly reduce unnecessary biopsies and overdiagnosis of prostate cancer. Different PHI reference ranges should be used for different ethnic groups.Copyright ©

2019 EvidenceUpdates

105. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up (Abstract)

with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could (...) result in considerable reductions of M+ disease and mortality which if confirmed in larger datasets should trigger further discussion on pros/cons of PCa screening. PATIENT SUMMARY: In a cohort with 19yr of follow-up, we found indications for a more substantial reduction in metastatic disease and cancer-specific mortality in favor of prostate cancer screening than previously reported. If confirmed in larger cohorts, these findings should be considered in the ongoing discussion on harms and benefits

2019 EvidenceUpdates

106. 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.

177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118. 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer - Repository of AIHTA GmbH English | Browse - - - 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Stanak, M. and Grössmann, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support (...) Document 118. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 930kB Abstract The majority of prostate cancer patients have an overexpressed prostate specific membrane antigen (PSMA) that is a target for radionuclide therapy. Our aim was to review the current evidence on clinical effectiveness and safety of 177 Lutetium (Lu) labelled PSMA for metastatic castration-resistant prostate cancer (mCRPC) patients. No controlled trials were found to answer the research

2019 Austrian Institute of Health Technology Assessment

107. Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.

Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88. Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC) - Repository of AIHTA GmbH English | Browse - - - Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC) Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic (...) castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 1MB Abstract Castration-resistant prostate cancer (CRPC) is a type of prostate cancer that keeps growing even when the testosterone level is reduced to very low. Darolutamide is a nonsteroidal androgen receptor (AR) antagonist with a molecular structure that differs from other AR antagonists. To date, darolutamide is neither approved

2019 Austrian Institute of Health Technology Assessment

108. Enzalutamide (Xtandi) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90.

Enzalutamide (Xtandi) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90. Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC) - Repository of AIHTA GmbH English | Browse - - - Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC) Rothschedl, E (...) . (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 912kB Abstract Patients with metastatic hormone-sensitive prostate cancer (mHSPC) have never received androgen deprivation therapy (ADT) before, and thus are sensitive to ADT. Enzalutamide (Xtandi®) is an androgen receptor inhibitor, which

2019 Austrian Institute of Health Technology Assessment

109. Prostate cancer: Scenario: Management of complications of prostate cancer and adverse effects of treatments

follow up and monitor men with prostate cancer? Men with prostate cancer should be followed up in primary care in line with locally agreed protocols. For all men, review and manage: of the disease, including pain, lower urinary tract symptoms, and symptoms of spinal cord compression. Adverse effects from treatment, including and . Adverse effects of androgen withdrawal include change in body shape and weight gain, tiredness, hot flushes, loss of libido, erectile dysfunction, gynaecomastia, and loss (...) and Care Excellence (NICE) guideline Prostate cancer: diagnosis and managemen t [ ] and expert opinion in a narrative review Radiation-induced small bowel disease: latest developments and clinical guidance [ ]. How should I manage sexual dysfunction in men with prostate cancer? Tell men (and, if they wish, their partner), before starting androgen deprivation therapy that it may cause a loss of libido and possible sexual function. Advise men about the possible loss of ejaculation and fertility

2019 NICE Clinical Knowledge Summaries

110. Algorithm for erectile rehabilitation following prostate cancer treatment

Algorithm for erectile rehabilitation following prostate cancer treatment Algorithm for erectile rehabilitation following prostate cancer treatment To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2019 Canadian Urological Association

111. Castration-resistant prostate cancer (CRPC): CUA/CUOG

Castration-resistant prostate cancer (CRPC): CUA/CUOG Castration-resistant prostate cancer (CRPC): CUA/CUOG To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2019 Canadian Urological Association

112. General medicine: MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis

General medicine: MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis Article Text Commentary General medicine MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis Ivo G Schoots 1 , 2 , Olivier Rouvière 3 , 4 Statistics from Altmetric.com Commentary on : Kasivisvanathan V, Rannikko

2019 Evidence-Based Medicine

113. Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

: No advisor on medical and scientific questions was available for the present dossier assessment. IQWiG employees involved in the dossier assessment: ? Bent Müller ? Christiane Balg ? Gertrud Egger ? Simone Johner ? Inga Overesch ? Anke Schulz ? Anja Schwalm ? Volker Vervölgyi Keywords: enzalutamide, prostatic neoplasms – castration-resistant, benefit assessment, NCT02003924 Extract of dossier assessment A18-80 Version 1.0 Enzalutamide (prostate cancer) 26 February 2019 Institute for Quality (...) Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Enzalutamid (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 February 2019). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

114. Apalutamide (prostate cancer) - Addendum to Commission A19-09

months), use of bone-preserving substances (yes vs. no), presence of locoregional disease (N0 vs. N1). b: Deterioration means decrease in score by the respective MID. ADT: androgen deprivation therapy; AE: adverse event; CI: confidence interval; CTCAE: Common Terminology Criteria for Adverse Events; FACT-P: Functional Assessment of Cancer Therapy – Prostate; HR: hazard ratio; MID: minimally important difference; n: number of patients with (at least one) event; N: number of analysed patients; NA (...) Apalutamide (prostate cancer) - Addendum to Commission A19-09 1 Translation of addendum A19-51 Apalutamid (Prostatakarzinom) – Addendum zum Auftrag A19-09 (Version 1.0; Status: 11 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 11 July 2019 1.0 Commission: A19-51 Version: Status: IQWiG Reports – Commission No. A19-51 Apalutamide (prostate

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

115. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. Full Text available with Trip Pro

Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. Radical prostatectomy reduces mortality among men with clinically detected localized prostate cancer, but evidence from randomized trials with long-term follow-up is sparse.We randomly assigned 695 men with localized prostate cancer to watchful waiting or radical prostatectomy from October 1989 through February 1999 and collected follow-up data through 2017. Cumulative incidence and relative risks with 95 (...) % confidence intervals for death from any cause, death from prostate cancer, and metastasis were estimated in intention-to-treat and per-protocol analyses, and numbers of years of life gained were estimated. We evaluated the prognostic value of histopathological measures with a Cox proportional-hazards model.By December 31, 2017, a total of 261 of the 347 men in the radical-prostatectomy group and 292 of the 348 men in the watchful-waiting group had died; 71 deaths in the radical-prostatectomy group

2018 NEJM Controlled trial quality: predicted high

116. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. (Abstract)

users and nonusers using an age-adjusted Cox regression model.Screening increased the detection of Gleason 6 (hazard ratio [HR] 1.59, 95% confidence interval [CI] 1.47-1.72 and HR 1.39, 95% CI 1.26-1.54) and localized prostate tumors (HR 1.25, 95% CI 1.18-1.32 and HR 1.11, 95% CI 1.03-1.20) more among baseline NSAID nonusers than among users, respectively (p for interaction <0.04 for both). This difference was observed in all three screening rounds. Detection of metastatic prostate cancer (...) was similar in both NSAID users and nonusers. Screening decreased prostate cancer mortality among men using NSAIDs at FinRSPC randomization (HR 0.66, 95% CI 0.49-0.90) but not among nonusers (HR 0.95, 95% CI 0.81-1.12); p for interaction=0.04.Screening detected fewer well-differentiated localized tumors among NSAID users than among nonusers. This suggests that PSA screening may cause less overdiagnosis within this subgroup, whereas mortality benefit may be greater among NSAID users.Prostate cancer

2018 European urology focus

117. Padeliporfin for untreated localised prostate cancer

techniques for prostate cancer are more accur New diagnostic techniques for prostate cancer are more accurate at identifying low- ate at identifying low- risk disease risk disease 3.1 NICE's clinical guideline on prostate cancer considers tumours to be low risk if the following criteria are met: serum prostate-specific antigen (PSA) no more than 10 ng/ml, a Gleason score no more than 6, and a clinical stage of T1 to T2a. (The Gleason Score is a grading system that rates the aggressiveness of the 2 (...) largest areas of prostate cancer cells in a tumour. Each area is scored on how healthy it looks, so healthy tissue scores 1 or 2 and abnormal tissue scores 3). The clinical experts explained that the techniques used to diagnose prostate cancer in the NHS are changing, for example, transrectal ultrasound (TRUS) guided biopsy is being replaced by multiparametric MRI. MRI techniques are more accurate at differentiating low-risk disease that does not need treatment, from disease that is likely to progress

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

118. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer Full Text available with Trip Pro

in a large cohort of men with prostate cancer highly enriched in an AA patient population.Patients were diagnosed with clinically localized adenocarcinoma of the prostate and treated at The Ochsner Clinic (New Orleans, LA, USA) from January 2006 to December 2011. CCP scores were derived from archival formalin-fixed, paraffin-embedded biopsy tissue. CCR scores were calculated as the combination of molecular (CCP score) and clinical (Cancer of the Prostate Risk Assessment [CAPRA] score) components.Active (...) Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer Better prostate cancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain.To evaluate the utility of both a cell cycle progression (CCP) score and a clinical cell-cycle risk (CCR) score to predict clinical outcomes

2018 EvidenceUpdates

119. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial Full Text available with Trip Pro

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial The NRG/RTOG 9413 study showed that whole pelvic radiotherapy (WPRT) plus neoadjuvant hormonal therapy (NHT) improved progression-free survival in patients with intermediate-risk or high-risk localised prostate cancer compared with prostate only radiotherapy (PORT) plus NHT, WPRT plus adjuvant hormonal therapy (AHT), and PORT plus (...) in the NHT plus WPRT group, 17 (5%) of 313 in the NHT plus PORT group, 22 (7%) of 317 in the WPRT plus AHT group, and 14 (4%) of 315 in the PORT plus AHT group. Late grade 3 or worse gastrointestinal adverse events occurred in 22 (7%) of 316 patients in the NHT plus WPRT group, five (2%) of 313 in the NHT plus PORT group, ten (3%) of 317 in the WPRT plus AHT group, and seven (2%) of 315 in the PORT plus AHT group.In this cohort of patients with intermediate-risk and high-risk localised prostate cancer

2018 EvidenceUpdates

120. Hypofractionated Radiation Therapy for Localized Prostate Cancer Full Text available with Trip Pro

Hypofractionated Radiation Therapy for Localized Prostate Cancer Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01097 Journal of Clinical Oncology - published online before print October 11, 2018 Hypofractionated Radiation Therapy (...) for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline x Scott C. Morgan , x Karen Hoffman , x D. Andrew Loblaw , x Mark K. Buyyounouski , x Caroline Patton , x Daniel Barocas , x Soren Bentzen , x Michael Chang , x Jason Efstathiou , x Patrick Greany , x Per Halvorsen , x Bridget F. Koontz , x Colleen Lawton , x C. Marc Leyrer , x Daniel Lin , x Michael Ray , and x Howard Sandler Scott C. Morgan, The Ottawa Hospital and University of Ottawa, Ottawa; D. Andrew Loblaw, Odette Cancer

2018 American Society of Clinical Oncology Guidelines